Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28%

Insmed Inc. (NASDAQ:INSM) is one of the 10 Stocks Leaving the Market in the Dust Today.

Insmed snapped a two-day losing streak on Monday, adding 5.52 percent to close at $153.32 apiece, as investors took path from Morgan Stanley’s rating and 28-percent price target upgrade for its stock.

In a market note, Morgan Stanley raised its price target for Insmed Inc. (NASDAQ:INSM) to $212 from $166 previously, as well as its rating to “overweight” from “equal weight” amid its optimism for the latter’s Brinsupri bronchiectasis launch. The figure marked a 38 percent upside potential from its latest closing price.

Is AtaiBeckley Inc (ATAI) Looking to Sell Its Flagship Psychedelic Drug Candidate BPL-003?

Photo from Pexels

The upgrade reflected its optimism for Insmed Inc.’s (NASDAQ:INSM) treatment for non-cystic fibrosis bronchiectasis (NCFB) called Brinsupri following a US pulmonology survey of 75 pulmonologists, indicating the treatment’s durability and depth in the product launch.

Based on the study, 85 percent of respondents have already prescribed Brinsupri, with a current patient share of 12 percent.

Pulmonologists expect the number to jump to 21 percent by the end of the year, implying a nearly double growth in just nine months.

During its fourth quarter earnings call, Insmed Inc. (NASDAQ:INSM) noted low discontinuation rates and refills progressing well for Brinsupri, with more optimistic feedback for the treatment.

While we acknowledge the risk and potential of INSM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INSM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.